FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer
| Autor: | Xueli Jia, Shilong Sun, Xiaowei Song, Shuang Xu, Linlin Liu, Kuang-Hui Lee, Baosheng Sun, Mingmei Huangfu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Uterine Cervical Neoplasms Antigen Antigens Neoplasm Surgical oncology Internal medicine Biomarkers Tumor medicine Humans Secretion Autoantibodies Cervical cancer biology business.industry Autoantibody Cancer FOXP3 Forkhead Transcription Factors Hematology General Medicine Middle Aged Prognosis medicine.disease biology.protein Female Surgery Antibody business |
| Zdroj: | International Journal of Clinical Oncology. 20:982-988 |
| ISSN: | 1437-7772 1341-9625 |
| DOI: | 10.1007/s10147-015-0797-4 |
| Popis: | Overexpression of tumor-associated antigens has been reported in many types of cancer and may trigger secretion of their autoantibodies. The present work was designed to test whether circulating antibody to FOXP3 protein-derived antigens was altered in early cervical cancer and cervical benign tumors.A total of 141 patients with cervical cancer, 133 patients with cervical benign tumors and 148 healthy age-matched volunteers were recruited. The level of circulating anti-FOXP3 IgG antibody was tested using an enzyme-linked immunosorbent assay developed in-house with linear peptide antigens derived from FOXP3 protein. The linear peptide antigens were designed according to the computational prediction of HLA-II epitopes.Student's t test showed that anti-FOXP3 IgG in the malignant tumor group and the benign tumor group was significantly higher than in the control group (t = 6.127, p0.001; t = 2.704, p = 0.007). In addition, patients with stage I cervical cancer (t = 2.968, p = 0.003) had a significantly higher level of FOXP3 autoantibodies than patients with benign tumors. The sensitivity against90 % specificity was 20.6 % with an interassay deviation of 11.7 % in the cervical cancer group. Based on a cut-off value determined by the 98th percentile of the control group IgG levels, the anti-FOXP3 IgG positivity was 2.1 % in patients with cervical cancer compared to 2.0 % in the health controls (chi-squared = 0.004, p = 0.952, OR = 1.051, 95 % CI 0.209-5.295).The circulating autoantibody to FOXP3 reflecting the continuous development of the cervical lesion, may be a potential biomarker with early prognostic values for cervical cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink